substance p has been researched along with Atherosclerotic Parkinsonism in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thornton, E; Vink, R | 1 |
| Lavoie, B; Parent, A | 1 |
| Drago, J; Finkelstein, DI; Kola, I; Lakso, M; Lawrence, AJ; McManus, JF; Natoli, AL; Padungchaichot, P; Sumarsono, SH; Westphal, H; Wong, JY; Wreford, N | 1 |
| Gresch, PJ; Walker, PD | 1 |
| Aoyama, S; Borrelli, E; Kase, H | 1 |
| Godlevskiĭ, LS; Kryzhanovskiĭ, GN; Kucherianu, VG; Mazarati, AD | 1 |
| Bennett, JP; Orosz, D | 1 |
| Allen, JM; Close, SP; Cross, AJ; Crow, TJ; Ghatei, MA; Marriott, AS; McGregor, GP; Pay, S; Tyers, MB; Yeats, JC | 1 |
| Cumming, P; Radke, JM; Vincent, SR | 1 |
| Barker, R | 1 |
| Atadzhanov, MA; Kryzhanovskiĭ, GN; Kucherianu, VG | 1 |
1 review(s) available for substance p and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Adrenal grafting for Parkinson's disease: a role for substance P.
Topics: Adrenal Medulla; Animals; Nerve Growth Factors; Parkinson Disease, Secondary; Substance P | 1989 |
10 other study(ies) available for substance p and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Cells; Dopaminergic Neurons; Inflammation; Male; Motor Activity; Neurokinin-1 Receptor Antagonists; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Substance P; Substantia Nigra; Tryptophan | 2012 |
The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys.
Topics: Animals; Brain Mapping; Calbindins; Corpus Striatum; Dopamine; Enkephalin, Methionine; Female; Immunoenzyme Techniques; Macaca fascicularis; Mesencephalon; Nerve Degeneration; Neural Pathways; Neurons; Parkinson Disease, Secondary; Receptors, Dopamine; S100 Calcium Binding Protein G; Substance P; Tyrosine 3-Monooxygenase | 1993 |
Targeted expression of a toxin gene to D1 dopamine receptor neurons by cre-mediated site-specific recombination.
Topics: Animals; Apoptosis; Basal Ganglia; Diphtheria Toxin; Enkephalins; Gene Expression Regulation, Enzymologic; Glial Fibrillary Acidic Protein; Gliosis; In Situ Hybridization; In Situ Nick-End Labeling; Integrases; Mice; Mice, Transgenic; Microscopy, Electron; Movement Disorders; Myoclonus; Neurons; Parkinson Disease, Secondary; Phenotype; Radioligand Assay; Receptors, Dopamine D1; RNA, Messenger; Substance P; Viral Proteins | 1998 |
Serotonin-2 receptor stimulation normalizes striatal preprotachykinin messenger RNA in an animal model of Parkinson's disease.
Topics: Amphetamines; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Gene Expression Regulation; In Situ Hybridization; Male; Neural Pathways; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; RNA, Messenger; Serotonin; Serotonin Receptor Agonists; Substance P; Substantia Nigra; Tachykinins | 1999 |
Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist.
Topics: Adenosine; Animals; Antihypertensive Agents; Antineoplastic Agents; Enkephalins; Gait; Gene Expression; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Parkinson Disease, Secondary; Phenethylamines; Purinergic P1 Receptor Antagonists; Purines; Radioligand Assay; Receptor, Adenosine A2A; Receptors, Dopamine D2; Receptors, Purinergic P1; RNA, Messenger; Substance P; Tritium | 2000 |
[Effects of intranasally administered substance P in parkinsonian syndrome].
Topics: Administration, Intranasal; Animals; Caudate Nucleus; Parkinson Disease, Secondary; Rats; Substance P | 1992 |
Baseline and apomorphine-induced extracellular levels of nigral substance P are increased in an animal model of Parkinson's disease.
Topics: Animals; Apomorphine; Dialysis; Disease Models, Animal; Dopamine; Ganglia, Sympathetic; Hydroxydopamines; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra | 1990 |
Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Callitrichinae; Cholecystokinin; Disease Models, Animal; Dopamine; Female; Kidney; Male; Neurotensin; Parkinson Disease, Secondary; Pyridines; Substance P; Vasoactive Intestinal Peptide | 1986 |
Effects of MPTP poisoning on central somatostatin and substance P levels in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Corpus Striatum; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Pyridines; Radioimmunoassay; Somatostatin; Substance P | 1987 |
[Effects of substance P on experimental parkinsonian syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Extrapyramidal Tracts; Male; Motor Cortex; Parkinson Disease, Secondary; Rats; Somatosensory Cortex; Substance P; Time Factors | 1989 |